分配II期和III期试验样本量以优化成功概率

Q3 Nursing
D. De Martini
{"title":"分配II期和III期试验样本量以优化成功概率","authors":"D. De Martini","doi":"10.2427/9958","DOIUrl":null,"url":null,"abstract":"\nBackground Clinical trials of phase II and III often fail due to poor experimental planning. Here, the problem of allocating available resources, in terms of sample size, to phase II and phase III is studied with the aim of increasing success rate. The overall success probability (OSP) is accounted for. \nMethods Focus is placed on the amount of resources that should be provided to phase II and III trials to attain a good level of OSP, and on how many of these resources should be allocated to phase II to optimize OSP. It is assumed that phase II data are not considered for confirmatory purposes and that are used for planning phase III through sample size estimation. Being $r$ the rate of resources allocated to phase II, $OSP(r)$ is a concave function and there exists an optimal allocation $r_{opt}$ giving $\\max\\{OSP\\}$. If $M_I$ is the sample size giving the desired power to phase III, and $kM_I$ is the whole sample size that can be allocated to the two phases, it is indicated how large $k$ and $r$ should be in order to achieve levels of OSP of practical interest. \nResults For example, when 5 doses are evaluated in phase II and 2 parallel phase III confirmatory trials (one-tail type I error $=2.5\\%$, power $=90\\%$) are considered with 2 groups each, $k=24$ is needed to obtain $OSP\\simeq 75\\%$, with $r_{opt}\\simeq 50\\%$. The choice of $k$ depends mainly on how many phase II treatment groups are considered, not on the effect size of the selected dose. When $k$ is large enough, $r_{opt}$ is close to $50\\%$. An $r\\simeq25\\%$, although not best, might give a good OSP and an invitingly small total sample size, provided that $k$ is large enough. \nConclusions To improve the success rate of phase II and phase III trials, the drug development could be looked at in its entirety. Resources larger than those usually employed should be allocated to phase II to increase OSP. Phase II allocation rate may be increased to, at least, 25\\%, provided that a sufficient global amount of resources is available. \n","PeriodicalId":45811,"journal":{"name":"Epidemiology Biostatistics and Public Health","volume":"159 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Allocating the Sample Size in Phase II and III Trials to Optimize Success Probability\",\"authors\":\"D. De Martini\",\"doi\":\"10.2427/9958\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\nBackground Clinical trials of phase II and III often fail due to poor experimental planning. Here, the problem of allocating available resources, in terms of sample size, to phase II and phase III is studied with the aim of increasing success rate. The overall success probability (OSP) is accounted for. \\nMethods Focus is placed on the amount of resources that should be provided to phase II and III trials to attain a good level of OSP, and on how many of these resources should be allocated to phase II to optimize OSP. It is assumed that phase II data are not considered for confirmatory purposes and that are used for planning phase III through sample size estimation. Being $r$ the rate of resources allocated to phase II, $OSP(r)$ is a concave function and there exists an optimal allocation $r_{opt}$ giving $\\\\max\\\\{OSP\\\\}$. If $M_I$ is the sample size giving the desired power to phase III, and $kM_I$ is the whole sample size that can be allocated to the two phases, it is indicated how large $k$ and $r$ should be in order to achieve levels of OSP of practical interest. \\nResults For example, when 5 doses are evaluated in phase II and 2 parallel phase III confirmatory trials (one-tail type I error $=2.5\\\\%$, power $=90\\\\%$) are considered with 2 groups each, $k=24$ is needed to obtain $OSP\\\\simeq 75\\\\%$, with $r_{opt}\\\\simeq 50\\\\%$. The choice of $k$ depends mainly on how many phase II treatment groups are considered, not on the effect size of the selected dose. When $k$ is large enough, $r_{opt}$ is close to $50\\\\%$. An $r\\\\simeq25\\\\%$, although not best, might give a good OSP and an invitingly small total sample size, provided that $k$ is large enough. \\nConclusions To improve the success rate of phase II and phase III trials, the drug development could be looked at in its entirety. Resources larger than those usually employed should be allocated to phase II to increase OSP. Phase II allocation rate may be increased to, at least, 25\\\\%, provided that a sufficient global amount of resources is available. \\n\",\"PeriodicalId\":45811,\"journal\":{\"name\":\"Epidemiology Biostatistics and Public Health\",\"volume\":\"159 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epidemiology Biostatistics and Public Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2427/9958\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiology Biostatistics and Public Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2427/9958","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 0

摘要

II期和III期临床试验往往由于实验计划不佳而失败。在此,研究了将可用资源按样本量分配到第二阶段和第三阶段的问题,目的是提高成功率。考虑了总体成功概率(OSP)。方法将重点放在应该向II期和III期试验提供多少资源以获得良好的OSP水平,以及应该将多少资源分配给II期以优化OSP。假定第二阶段的数据不用于确认目的,并通过样本量估计用于规划第三阶段。为第二期资源分配率$r$, $OSP(r)$是一个凹函数,存在一个最优分配$r_{opt}$,给出$\max\{OSP\}$。如果$M_I$是为第三阶段提供所需功率的样本量,$kM_I$是可以分配给两个阶段的整个样本量,则表明$k$和$r$应该有多大才能达到实际感兴趣的OSP水平。结果例如,考虑5个剂量的II期评价和2个平行的III期验证性试验(单尾I型误差$=2.5\%$,功率$=90\%$),每组考虑2组,则需要$k=24$得到$OSP\simeq 75\%$,再加上$r_{opt}\simeq 50\%$。$k$的选择主要取决于考虑了多少个II期治疗组,而不是所选剂量的效应大小。当$k$足够大时,$r_{opt}$接近$50\%$。$r\simeq25\%$虽然不是最好的,但如果$k$足够大,它可能会给出一个很好的OSP和一个诱人的小总样本量。结论为了提高二期和三期临床试验的成功率,可以从整体上看待药物的开发。应将比通常使用的资源更多的资源分配给第二阶段,以增加OSP。在全球资源充足的情况下,第二阶段的分配率可提高到至少25%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Allocating the Sample Size in Phase II and III Trials to Optimize Success Probability
Background Clinical trials of phase II and III often fail due to poor experimental planning. Here, the problem of allocating available resources, in terms of sample size, to phase II and phase III is studied with the aim of increasing success rate. The overall success probability (OSP) is accounted for. Methods Focus is placed on the amount of resources that should be provided to phase II and III trials to attain a good level of OSP, and on how many of these resources should be allocated to phase II to optimize OSP. It is assumed that phase II data are not considered for confirmatory purposes and that are used for planning phase III through sample size estimation. Being $r$ the rate of resources allocated to phase II, $OSP(r)$ is a concave function and there exists an optimal allocation $r_{opt}$ giving $\max\{OSP\}$. If $M_I$ is the sample size giving the desired power to phase III, and $kM_I$ is the whole sample size that can be allocated to the two phases, it is indicated how large $k$ and $r$ should be in order to achieve levels of OSP of practical interest. Results For example, when 5 doses are evaluated in phase II and 2 parallel phase III confirmatory trials (one-tail type I error $=2.5\%$, power $=90\%$) are considered with 2 groups each, $k=24$ is needed to obtain $OSP\simeq 75\%$, with $r_{opt}\simeq 50\%$. The choice of $k$ depends mainly on how many phase II treatment groups are considered, not on the effect size of the selected dose. When $k$ is large enough, $r_{opt}$ is close to $50\%$. An $r\simeq25\%$, although not best, might give a good OSP and an invitingly small total sample size, provided that $k$ is large enough. Conclusions To improve the success rate of phase II and phase III trials, the drug development could be looked at in its entirety. Resources larger than those usually employed should be allocated to phase II to increase OSP. Phase II allocation rate may be increased to, at least, 25\%, provided that a sufficient global amount of resources is available.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Epidemiology Biostatistics and Public Health
Epidemiology Biostatistics and Public Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
自引率
0.00%
发文量
0
期刊介绍: Epidemiology, Biostatistics, and Public Health (EBPH) is a multidisciplinary journal that has two broad aims: -To support the international public health community with publications on health service research, health care management, health policy, and health economics. -To strengthen the evidences on effective preventive interventions. -To advance public health methods, including biostatistics and epidemiology. EBPH welcomes submissions on all public health issues (including topics like eHealth, big data, personalized prevention, epidemiology and risk factors of chronic and infectious diseases); on basic and applied research in epidemiology; and in biostatistics methodology. Primary studies, systematic reviews, and meta-analyses are all welcome, as are research protocols for observational and experimental studies. EBPH aims to be a cross-discipline, international forum for scientific integration and evidence-based policymaking, combining the methodological aspects of epidemiology, biostatistics, and public health research with their practical applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信